Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Other financing activities (2020 - 2025)

Immuneering's Other financing activities history spans 4 years, with the latest figure at $587355.0 for Q4 2025.

  • On a quarterly basis, Other financing activities rose 1332.99% to $587355.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $914717.0, a 618.2% increase, with the full-year FY2025 number at $3.7 million, up 8991.11% from a year prior.
  • Other financing activities came in at $587355.0 for Q4 2025, up from $200000.0 in the prior quarter.
  • The five-year high for Other financing activities was $587355.0 in Q4 2025, with the low at $40988.0 in Q4 2024.
  • Historically, Other financing activities has averaged $199348.7 across 3 years, with a median of $143187.0 in 2024.
  • Peak annual rise in Other financing activities hit 1332.99% in 2025, while the deepest fall reached 131.55% in 2025.
  • Year by year, Other financing activities stood at $226775.0 in 2022, then plummeted by 81.93% to $40988.0 in 2024, then soared by 1332.99% to $587355.0 in 2025.
  • Business Quant data shows Other financing activities for IMRX at $587355.0 in Q4 2025, $200000.0 in Q3 2025, and $40988.0 in Q4 2024.